Aim: Pharmacological treatment for metabolic syndromerelated non-alcoholic steatohepatitis has not been established. We investigated the effect of L-carnitine, an essential substance for β-oxidation, on metabolic steatohepatitis in mice.
INTRODUCTION
N ON-ALCOHOLIC FATTY LIVER disease (NAFLD) is a broad spectrum of hepatic disorders characterized by evidence of hepatic steatosis either by imaging or histology, and appropriate exclusion of other etiologies such as heavy alcohol consumption, hepatitis viruses, and autoimmunity.
1 Non-alcoholic steatohepatitis (NASH) is a progressive form of NAFLD, eventually leading to liver cirrhosis and cancer. The incidence of NASH is increasing worldwide, 2 and is currently the third most common indication for liver transplantation. 3 Non-alcoholic steatohepatitis is recognized as the hepatic manifestation of metabolic syndrome, as obesity, insulin resistance, and dyslipidemia contribute profoundly to the development of NASH. [4] [5] [6] The pathogenesis of NASH still remains to be fully elucidated, and the pharmacotherapy of metabolic syndrome-related NASH has not been well established.
L-carnitine, a vitamin-like constituent of protein, is indispensable for mitochondrial β-oxidation, by which free fatty acids (FFA) are catabolized. 7 Systemic primary carnitine deficiency is typically characterized by episodes of hypoketotic hypoglycemia and hepatomegaly due to hepatic steatosis with elevated serum aminotransferases and ammonia levels in infants, which are markedly resolved by L-carnitine intake. 8 Acquired deficiency of L-carnitine is often seen in patients undergoing hemodialysis, in which supplementation of L-carnitine has been proved to enhance the efficacy of erythropoietin on renal anemia, and ameliorate intradialytic symptoms. 9, 10 Depletion of L-carnitine also occurs following long-term treatment with certain drugs such as pivalate-generating prodrugs and valproic acid, and L-carnitine supplementation has been shown to improve hyperammonemia in psychiatric patients receiving valproic acid. 9, 1111 Some clinical trials have recently suggested the potential efficacy of L-carnitine in patients with NAFLD. 12, 13 It has been reported that Lcarnitine prevents streptozotocin-induced steatohepatitis and subsequent hepatocarcinogenesis in a murine model (STAM mice); 14 however, the effect of L-carnitine on metabolic syndrome-related NASH is still unclear.
KK-A y mice are a strain generated from diabetic KK mice by introducing lethal yellow (A y ) mutation, which causes aberrant expression of the agouti gene on chromosome 2. KK-A y mice show a phenotype similar to human metabolic syndrome including obesity, dyslipidemia, and insulin resistance, in combination with spontaneous development of steatohepatitis; thus this animal is potentially useful as a model of NAFLD/NASH. 15 We have reported that KK-A y mice show increased susceptibility to methionine-and choline-deficiency diet-induced steatohepatitis, 16 and acetaminophen-induced liver injury. 17 We also reported that KK-A y mice show proportional and functional alterations in hepatic natural killer T cells, 18 and impaired in liver regeneration after partial hepatectomy. 19 KK-A y mice fed a high-fat diet (HFD) develop more severe steatohepatitis, 20, 21 resembling metabolic syndrome-related NASH.
Therefore, our aim in this study was to investigate the effect of L-carnitine on metabolic syndrome-related steatohepatitis in KK-A y mice fed HFD.
METHODS

Animal experiments
T HE EXPERIMENTAL PROTOCOLS were approved by the Committee of Laboratory Animals according to institutional guidelines. Male, 7-week-old KK-A y mice were purchased from CLEA Japan (Tokyo, Japan). Mice were housed in air-conditioned, specific pathogen-free animal quarters with lighting from 0800 to 2000 throughout this study, and were given unrestricted access to a standard laboratory chow and water during the 1-week acclimation period. After acclimation, 8-week-old KK-A y mice were fed an HFD (HFD32; CLEA Japan) (Table 1) for 8 weeks. Following an initial 4-week feeding period, some animals were treated with L-carnitine hydrochloride solution (1.25 mg/mL in drinking water; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) for 4 weeks. KK-A y mice fed normal chow for 4 weeks were used as controls. After dietary treatment with/without L-carnitine supplementation, overnight-fasted mice were killed by exsanguination from the inferior vena cava under ether anesthesia, and liver and serum samples were obtained. Serum and tissue samples for RNA preparation were kept frozen at À80°C until assayed.
Histological analysis and immunohistochemistry
For histological evaluation, liver tissues were fixed in 10% buffered formalin and embedded in paraffin, and hematoxylin-eosin staining was carried out. Caspase cleavage product of cytokeratin (ccCK) 18 was detected by immunohistochemistry using M30 CytoDEATH monoclonal antibody (Roche, Basel, Switzerland) as described previously. 22 Briefly, deparaffinized tissue sections were incubated with a monoclonal anti-M30 antibody and secondary biotinylated anti-mouse immunoglobulin G, and the specific binding was visualized with avidin-biotin complex solution followed by incubation with a 3, 3-diaminobenzidine tetrahydrochloride solution using a Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA). Specimens were observed under an optical microscope (DM7000; Leica, Wetzlar, Germany) equipped with a digital microscope camera (MC120HD; Leica), and digital images were captured.
Electron microscope analysis
A portion of liver specimen was immersed in fixative containing 3% glutaraldehyde in 0.1 mol/L phosphate buffer (pH 7.4) at 4°C for 24 h. Ultrathin sections of liver were prepared, and observed by transmission electron microscopy as described previously. 23 
Blood biochemistry
Serum aspartate aminotransferase, alanine aminotransferase, triglyceride, and glucose levels were determined using a Fuji DRI-CHEM system (Fuji Film Medical Co. Ltd., Tokyo, Japan). 
Measurement of carnitine
Serum total and free carnitine were measured by the enzymatic cycling method using commercial kits (KAINOS Laboratories Inc., Tokyo, Japan) following the manufacturer's instructions. Acyl-carnitine was calculated as the difference between total and free carnitine.
Measurement of FFA
Serum and hepatic FFA contents were measured by an enzyme-based method using the Free Fatty Acid Quantification Kit (BioVision, Milpitas, CA, USA) following the manufacturer's instructions. The amount of hepatic FFA content was normalized by weight of tissue samples.
Measurement of ketone bodies
β-Hydroxybutyrate in liver tissue was measured using a β-hydroxybutyrate (ketone body) Fluorometric Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA). Briefly, 50 mg liver tissue was homogenized in 300 mL buffer using a Teflon homogenizer. Homogenate was mixed with the equivalent volume of 1 mol/L metaphosphoric acid, and centrifuged at 10 000 g for 5 min. The pellet was dissolved in 60 μL of 5 mol/L potassium carbonate solution. After centrifugation at 10 000 g for 5 min, supernatant was collected, and 25 μL supernatant was then mixed with the equal volume of β-hydroxybutyrate dehydrogenase solution. After 30 min incubation at 37°C, fluorescence was measured using a fluorescence spectrophotometer with excitation and emission wavelength of 530-540 nm and 585-595 nm, respectively. The amount of hepatic β-hydroxybutyrate content was normalized by weight of tissue samples.
Measurement of adenosine 5'-triphosphate
The adenosine 5'-triphosphate (ATP) content in liver tissue was measured by luciferase assay using an ATP assay kit for animal tissues (TOYO B-Net Co., Ltd., Tokyo, Japan) following the manufacturer's instructions.
Enzyme-linked immunosorbent assay
Serum insulin levels were measured using the Mouse Insulin enzyme-linked immunosorbent assay (ELISA) Kit (Morinaga Institute of Biological Sciences, Inc., Kanagawa, Japan). Serine phosphorylation of insulin receptor substrate (IRS)-1 in liver tissue was determined using the PathScan Phospho-IRS-1 (Ser307) Sandwich ELISA Kit (Cell Signaling Technology, Danvers, MA, USA).
RNA preparation and real-time reverse transcription-polymerase chain reaction
Total RNA was prepared from frozen tissue samples using the illustra RNAspin Mini RNA Isolation kit (GE Healthcare, Waukesha, WI, USA) as described previously. 24 The concentration and purity of isolated RNA were determined by measuring optical density at 260 and 280 nm. For real-time reverse transcription-polymerase chain reaction, total RNA (1 μg) was reverse transcribed using Moloney murine leukemia virus transcriptase (SuperScript II; Invitrogen, Carlsbad, CA, USA) and an oligo (dT) 12-18 primer at 42°C for 1 h. Obtained cDNA (1 μg) was amplified using Fast SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) and specific primers for carnitine palmitoyltransferase 1A (CPT1A; forward, 5′-GCC TCA GCG TGG AAC ACT CA-3′; reverse, 5′-CTG TGG CAT AAC CCA ACT GGA AG-3′), sterol regulatory element binding protein-1c (SREBP1c; forward, 5′-ACA GTC CAG CCT TTG AGG ATA G-3′; reverse, 5′-GAC ACA GAA AGG CCA GTA CAC A-3′), and glyceraldehyde-3-phosphate dehydrogenase (forward, 5′-TGT GTC CGT CGT GGA TCT GA-3′; reverse, 5′-TTG CTG TTG AAG TCG CAG GAG-3′). After a 10-s activation period at 95°C , 40 cycles of 95°C for 5 s and 60°C for 31 s, followed by a final cycle of 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s, were carried out using the ABI PRISM 7700 sequence detection system (Applied Biosystems), and the threshold cycle values were obtained.
Statistical analysis
Morphometric and densitometric analyses were carried out using Scion Image (version Beta 4.0.2; Scion Corp., Fredrick, MD, USA). Data were expressed as mean ± stanndard error of the mean. Statistical differences between means were determined using one-way ANOVA or Kruskal-Wallis ANOVA on ranks followed by an all pairwise multiple comparison procedure (Student-Newman-Keuls method) as appropriate. P < 0.05 was selected before the study to reflect significance.
RESULTS
L-carnitine blunts body weight gain and increases serum carnitine levels in KK-A y mice H IGH-FAT DIET-FED KK-A Y mice gained body weight rapidly, the values reaching 54.5 ± 0.9 g and 61.4 ± 0.9 g after 4 and 8 weeks, respectively. Treatment with L-carnitine, started after 4 weeks of prefeeding, significantly prevented body weight gain almost completely, with values 8 weeks after HFD feeding only reaching 54.2 ± 2.0 g (P < 0.05) (Fig. 1a) .
To evaluate the status of carnitine insufficiency, we measured serum total and free carnitine levels. Total carnitine levels were significantly lower in KK-A y mice fed HFD for 4 weeks compared with mice fed a control diet. However, serum free carnitine levels, which reflect the amount of dietary intake and synthesis in liver/kidney, 9 were not decreased following HFD feeding. In turn, serum levels of acyl-carnitine were significantly lower in HFD-fed mice, indicating that systemic consumption of carnitine was increased by HFD feeding. As expected, total carnitine levels were elevated to near basal levels when mice were given L-carnitine for 4 consecutive weeks. Treatment with L-carnitine also significantly increased both acyl and free carnitine (Fig. 1b-d) .
L-carnitine ameliorates hepatic steatosis in KK-A y mice
As expected, massive fat accumulation in hepatocytes with ballooning degeneration was observed 8 weeks after HFD feeding, which was dramatically prevented by administration of L-carnitine ( Fig. 2a-d) . Liver / body ratio was increased 8 weeks after HFD feeding, whereas the levels were significantly decreased in mice given L-carnitine (P < 0.05) (Fig. 2e) . There was no significant difference in food consumption between mice treated with/without L-carnitine. Serum aspartate aminotransferase and alanine aminotransferase levels were significantly elevated in mice fed HFD, the values reaching 112.2 ± 26.5 IU/L and 113.0 ± 31.5 IU/L after 8 weeks, respectively. These elevations were significantly blunted in mice treated with L-carnitine to 77.2 ± 3.4 IU/L and 28.8 ± 4.4 IU/L, respectively (P < 0.05) (Fig. 2f,g ).
L-carnitine prevents HFD-induced apoptosis of hepatocytes in KK-A y mice
To evaluate apoptosis of hepatocytes, immunohistological staining for ccCK18 was carried out using an M30 CytoDEATH antibody. High-fat diet feeding increased the number of ccCK18-positive cells to 20.9 ± 1.8 per field at 4 weeks, followed by further increase to 41.6 ± 0.9% after L-carnitine prevents murine steatohepatitis E47 Hepatology Research 2017; 47: E44-E54 8 weeks (P < 0.05). Surprisingly, the increase in apoptotic cell death was markedly prevented in mice treated with Lcarnitine to 10.5 ± 2.4% (P < 0.05) (Fig. 3) .
L-carnitine prevents hyperlipidemia following inhibition of de novo lipogenesis and activation of β-oxidation
In KK-A y mice, HFD feeding for 8 weeks significantly increased serum FFA and triglyceride levels to 170.1 ± 14.9 μmol/L and 347.0 ± 66.8 mg/dL, which were significantly decreased by treatment with L-carnitine to 65.1 ± 7.1 μmol/L and 71.0 ± 4.3 mg/dL, respectively (P < 0.05) (Fig. 4a,b) . Expression of SREBP1c mRNA in liver was measured to evaluate the effect of L-carnitine on de novo lipogenesis in HFD-fed mice. The treatment with L-carnitine completely prevented overexpression of SREBP1c mRNA induced by HFD to basal levels (P < 0.05) (Fig. 4c) . To analyze the activity of lipolysis, expression of CPT1A mRNA, the liver isoform of CPT1, 25 and production of β-hydroxybutyrate in liver were evaluated. Exposure to HFD significantly increased expression of CPT1A mRNA (Fig. 4d) but not increased β-hydroxybutyrate in liver after 8 weeks. Treatment with Lcarnitine markedly increased β-hydroxybutyrate to values more than twice that in mice fed HFD for 8 weeks (P < 0.05) (Fig. 4e) .
L-carnitine improves hyperglycemia and hyperinsulinemia in HFD-fed KK-A y mice
High-fat diet feeding significantly increased fasting serum glucose and insulin levels to 468.8 ± 64.5 mg/dL and 37.3 ± 5.5 ng/mL at 8 weeks, respectively, which were significantly decreased by treatment with L-carnitine to 217.2 ± 30.0 mg/dL and 4.4 ± 1.3 ng/mL, respectively (P < 0.05) ( Fig. 5a,b) . Serine 307 phosphorylation of IRS-1, detected by sandwich ELISA, was significantly increased at 4 weeks of HFD feeding, which was completely reversed to basal levels by treatment with L-carnitine (P < 0.05) (Fig. 5c ).
L-carnitine reduces FFA content and improves mitochondrial morphology and ATP production in liver
After 1 week of treatment, L-carnitine significantly reduced hepatic FFA content increased by HFD feeding (P < 0.05) (Fig. 6a) . In morphological analysis using an electron microscope, hepatocyte mitochondria in mice fed HFD showed overt swelling in shape with few cristae. Treatment with L-carnitine dramatically improved the mitochondrial morphology to a near-normal, oval shape with more cristae (Fig. 6b,c) . The HFD enhanced production of ATP in liver tissue, whereas addition of L-carnitine further increased the values, reaching more than twofold baseline levels (P < 0.05) (Fig. 6d) .
DISCUSSION
I
N THE PRESENT study, we showed that treatment with L-carnitine dramatically attenuates massive hepatic steatosis in KK-A y mice, even under conditions of continuous HFD feeding (Fig. 2) . L-carnitine primarily acts as a transport carrier of long-chain fatty acids across the inner mitochondrial membrane from cytosol into the mitochondrial matrix, where fatty acids are catalyzed through β-oxidation. 26, 275 Acyl-coenzyme A (CoA) units, formed by fatty acids and a CoA group, are converted into carnitine esters in a reaction catalyzed by CPT1, and subsequently cross the mitochondrial inner membrane. 27 Acetyl CoA produced by β-oxidation feeds into the citric acid cycle, and is converted to ketone bodies such as β-hydroxybutyrate. Here, the hepatic expression of CPT1A mRNA was increased following HFD intake (Fig. 4d) ; however, production of β-hydroxybutyrate in the liver was not increased by HFD alone. In contrast, HFD feeding supplemented with L-carnitine showed marked enhancement of β-hydroxybutyrate production in the liver (Fig. 4e) . Furthermore, hepatic ATP content was significantly increased by L-carnitine treatment (Fig. 6d) , suggesting the upregulation of ATP generation by the citric acid cycle and subsequent electron transport chain. Taken together, these findings clearly indicate that supplementation with L-carnitine, in concert with upregulation of CPT1A, is essential for the acceleration of mitochondrial β-oxidation in the liver under lipid overload.
L-carnitine markedly prevented overexpression of SREBP-1c mRNA induced by HFD feeding (Fig. 4c) , which is the main transcription factor regulating de novo lipogenesis. 28 As the insulin signaling pathway involving IRS-2/phosphoinositide 3-kinase positively regulates the expression of SREBP1c, 29 hyperinsulinemia most likely contributes to upregulation of SREBP1c in KK-A y mouse liver. It is therefore hypothesized that L-carnitine decreases expression of SREBP1c, at least in part, through normalization of hyperinsulinemia (Fig. 5b) .
Our data clearly indicated that L-carnitine not only attenuates hepatic steatosis but also prevents the progression of steatohepatitis, as L-carnitine prevented hepatocyte apoptosis, the key event of the development of metabolic syndrome-related steatohepatitis. 30 The effect of L-carnitine on hepatic fibrogenesis, however, remains to be elucidated, because the model used in this study only represents the early phase of steatohepatitis. Importantly, L-carnitine markedly reduced FFA levels in both serum and hepatic tissue (Figs. 4a,6a) , most likely as a result of enhanced β-oxidation in liver and peripheral tissues including skeletal muscle. As FFA promotes lipotoxicity in the pathogenesis of steatohepatitis, 31 it is likely that L-carnitine prevented HFD-induced steatohepatitis in KK-A y mice through amelioration of lipotoxicity by reduction of FFA content in hepatocytes. Furthermore, electron microscope analysis revealed that treatment with L-carnitine improved mitochondrial morphology in mice fed HFD (Fig. 6b,c) . These findings are consistent with a previous study showing that L-carnitine reverses mitochondrial dysfunction caused by FFA in vitro. 32 Excess FFA induces mitochondrial injury, which results in the failure of ATP production, thus leading to cell death in hepatocytes. 33 Therefore, increases in hepatic ATP content following L-carnitine treatment (Fig. 6d ) also supported the hypothesis that mitochondrial dysfunction caused by HFD feeding was rescued by supplementation with L-carnitine.
Another interesting observation in this study is that L-carnitine significantly prevented body weight gain in KK-A y mice during HFD feeding (Fig. 1a) , which is consistent with previous reports using mouse models fed HFD 34 and irregular diets. 35 The reduction of body weight by L-carnitine has also been reported in obese patients with metabolic syndrome 36 and polycystic ovary syndrome. 37 Moreover, L-carnitine improved hyperlipidemia, hyperglycemia, and hyperinsulinemia (Figs. 4a,b,5a,b) , which are the hallmarks of metabolic syndrome and the established risk factors for NASH. 38, 39 In terms of glucose metabolism, some reports have shown that L-carnitine improves insulin resistance in humans; 10, 36, 37, 40 however, the mechanism underlying the effect of L-carnitine on insulin resistance is not fully understood. Here, we showed that L-carnitine prevents increases in serine phosphorylation of IRS-1 (Ser307; Ser312 in human IRS-1), which negatively regulates insulin signaling, 41 in the liver following HFD feeding (Fig. 5c) . Lines of evidence have shown that serine phosphorylation of IRS-1 is induced by excess FFA. Therefore, it is likely that L-carnitine prevents HFDinduced serine phosphorylation of IRS-1, in part through decreasing hepatic FFA content (Fig. 6a) , thereby improving insulin signaling. Taken together, our findings indicate that L-carnitine is promising to prevent development of NASH, in combination with systemic features of metabolic syndrome based on insulin resistance.
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In conclusion, L-carnitine significantly ameliorates dietary steatohepatitis in KK-A y mice, in concert with improvement of metabolic abnormalities. The underlying mechanisms most likely involve L-carnitine augmentation of mitochondrial β-oxidation, which reduces excess hepatic FFA content, thereby attenuating lipotoxicity that causes metabolic abnormalities and cellular damage in hepatocytes. It is therefore postulated that supplementation of L-carnitine is a promising approach for prevention and treatment of metabolic syndrome-related NASH. 
